Role of Membrane-embedded Drug Efflux ABC Transporters in the Cancer Chemotherapy

Overview

Journal Oncol Rev

Specialty Oncology

Date 2020 Jul 18

PMID 32676170

Citations 31

Authors

Sonu Kumar Gupta

Priyanka Singh

Villayat Ali

Malkhey Verma

Affiliations

Soon will be listed here.

Abstract

One of the major problems being faced by researchers and clinicians in leukemic treatment is the development of multidrug resistance (MDR) which restrict the action of several tyrosine kinase inhibitors (TKIs). MDR is a major obstacle to the success of cancer chemotherapy. The mechanism of MDR involves active drug efflux transport of ABC superfamily of proteins such as Pglycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC2), and breast cancer resistance protein (BCRP/ABCG2) that weaken the effectiveness of chemotherapeutics and negative impact on the future of anticancer therapy. In this review, the authors aim to provide an overview of various multidrug resistance (MDR) mechanisms observed in cancer cells as well as the various strategies developed to overcome these MDR. Extensive studies have been carried out since last several years to enhance the efficacy of chemotherapy by defeating these MDR mechanisms with the use of novel anticancer drugs that could escape from the efflux reaction, MDR modulators or chemosensitizers, multifunctional nanotechnology, and RNA interference (RNAi) therapy.

Citing Articles

Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: advancing precision oncology.

Radhakrishnan A, Shanmukhan N, Samuel L Med Oncol. 2025; 42(3):67.

PMID: 39913003 DOI: 10.1007/s12032-025-02611-w.

Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.

Kadry M, Abd-Ellatef G, Ammar N, Hassan H, Hussein N, Kamel N Toxicol Rep. 2025; 14:101884.

PMID: 39886047 PMC: 11780168. DOI: 10.1016/j.toxrep.2024.101884.

Mechanosensitive nuclear uptake of chemotherapy.

Scott N, Kang S, Parekh S Sci Adv. 2024; 10(51):eadr5947.

PMID: 39693448 PMC: 11654694. DOI: 10.1126/sciadv.adr5947.

Soloxolone -3-(Dimethylamino)propylamide Restores Drug Sensitivity of Tumor Cells with Multidrug-Resistant Phenotype via Inhibition of P-Glycoprotein Efflux Function.

Moralev A, Salomatina O, Salakhutdinov N, Zenkova M, Markov A Molecules. 2024; 29(20).

PMID: 39459307 PMC: 11510211. DOI: 10.3390/molecules29204939.

Highly restrictive and directional penetration of the blood cerebral spinal fluid barrier by JCPyV.

OHara B, Lukacher A, Garabian K, Kaiserman J, MacLure E, Ishikawa H PLoS Pathog. 2024; 20(7):e1012335.

PMID: 39038049 PMC: 11293668. DOI: 10.1371/journal.ppat.1012335.

References

Krishna R, Mayer L . Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11(4):265-83. DOI: 10.1016/s0928-0987(00)00114-7. View

Gillet J, Gottesman M . Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2009; 596:47-76. DOI: 10.1007/978-1-60761-416-6_4. View

Kunjachan S, Rychlik B, Storm G, Kiessling F, Lammers T . Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013; 65(13-14):1852-1865. PMC: 3939439. DOI: 10.1016/j.addr.2013.09.018. View

Sawyers C . Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 2002; 1(1):13-5. DOI: 10.1016/s1535-6108(02)00022-3. View

Nies A, Keppler D . The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2006; 453(5):643-59. DOI: 10.1007/s00424-006-0109-y. View

Huisman M, Smit J, Schinkel A . Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000; 14(3):237-42. DOI: 10.1097/00002030-200002180-00005. View

Vasiliou V, Vasiliou K, Nebert D . Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009; 3(3):281-90. PMC: 2752038. DOI: 10.1186/1479-7364-3-3-281. View

Chen K, Sikic B . Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 2012; 18(7):1863-9. PMC: 3359695. DOI: 10.1158/1078-0432.CCR-11-1590. View

Mechetner E, Roninson I . Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992; 89(13):5824-8. PMC: 402110. DOI: 10.1073/pnas.89.13.5824. View

10.

Wu H, Hait W, Yang J . Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003; 63(7):1515-9. View

11.

Cherigo L, Lopez D, Martinez-Luis S . Marine natural products as breast cancer resistance protein inhibitors. Mar Drugs. 2015; 13(4):2010-29. PMC: 4413197. DOI: 10.3390/md13042010. View

12.

Kelly R, Draper D, Chen C, Robey R, Figg W, Piekarz R . A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2010; 17(3):569-80. PMC: 3071989. DOI: 10.1158/1078-0432.CCR-10-1725. View

13.

Mo W, Zhang J . Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012; 3(1):1-27. PMC: 3325772. View

14.

Jedlitschky G, Hoffmann U, Kroemer H . Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. 2006; 2(3):351-66. DOI: 10.1517/17425255.2.3.351. View

15.

Dorner B, Kuntner C, Bankstahl J, Bankstahl M, Stanek J, Wanek T . Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem. 2009; 52(19):6073-82. PMC: 3690441. DOI: 10.1021/jm900940f. View

16.

Kemper E, Cleypool C, Boogerd W, Beijnen J, van Tellingen O . The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol. 2003; 53(2):173-8. DOI: 10.1007/s00280-003-0720-y. View

17.

Prouillac C, Videmann B, Mazallon M, Lecoeur S . Induction of cells differentiation and ABC transporters expression by a myco-estrogen, zearalenone, in human choriocarcinoma cell line (BeWo). Toxicology. 2009; 263(2-3):100-7. DOI: 10.1016/j.tox.2009.06.023. View

18.

Verma M, Karimiani E, Byers R, Rehman S, Westerhoff H, Day P . Mathematical modelling of miRNA mediated BCR.ABL protein regulation in chronic myeloid leukaemia vis-a-vis therapeutic strategies. Integr Biol (Camb). 2013; 5(3):543-54. DOI: 10.1039/c3ib20230e. View

19.

Janneh O, Jones E, Chandler B, Owen A, Khoo S . Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007; 60(5):987-93. DOI: 10.1093/jac/dkm353. View

20.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View